JP2025511854A5 - - Google Patents
Info
- Publication number
- JP2025511854A5 JP2025511854A5 JP2024559398A JP2024559398A JP2025511854A5 JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5 JP 2024559398 A JP2024559398 A JP 2024559398A JP 2024559398 A JP2024559398 A JP 2024559398A JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleotide sequence
- human subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329081P | 2022-04-08 | 2022-04-08 | |
| US63/329,081 | 2022-04-08 | ||
| US202263401858P | 2022-08-29 | 2022-08-29 | |
| US63/401,858 | 2022-08-29 | ||
| PCT/US2023/065487 WO2023196941A1 (en) | 2022-04-08 | 2023-04-07 | Treatment of a non-alcoholic fatty liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511854A JP2025511854A (ja) | 2025-04-16 |
| JP2025511854A5 true JP2025511854A5 (cg-RX-API-DMAC7.html) | 2026-04-09 |
Family
ID=86286479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559398A Pending JP2025511854A (ja) | 2022-04-08 | 2023-04-07 | 非アルコール性脂肪肝疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250283089A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504337A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511854A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119789859A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247602A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196941A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025074157A1 (en) * | 2023-10-06 | 2025-04-10 | Glaxosmithkline Intellectual Property (No.3) Limited | Treatment of a non-alcoholic fatty liver disease |
| TW202540424A (zh) * | 2024-02-03 | 2025-10-16 | 大陸商北京福元醫藥股份有限公司 | 用於抑制HSD17B13表達的siRNA、其綴合物和藥物組合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| US12534728B2 (en) | 2018-09-19 | 2026-01-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use |
| KR20220158011A (ko) * | 2020-03-26 | 2022-11-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법 |
-
2023
- 2023-04-07 CN CN202380045597.9A patent/CN119789859A/zh active Pending
- 2023-04-07 CA CA3247602A patent/CA3247602A1/en active Pending
- 2023-04-07 WO PCT/US2023/065487 patent/WO2023196941A1/en not_active Ceased
- 2023-04-07 JP JP2024559398A patent/JP2025511854A/ja active Pending
- 2023-04-07 US US18/854,700 patent/US20250283089A1/en active Pending
- 2023-04-07 EP EP23721243.6A patent/EP4504337A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7674420B2 (ja) | Ldhaの発現を阻害するための方法及び組成物 | |
| JP2022501040A5 (cg-RX-API-DMAC7.html) | ||
| ES2676146T3 (es) | Composiciones de ARNi de Serpina1 y métodos de uso de las mismas | |
| JP6370860B2 (ja) | 被験体におけるsmn2スプライシングのモジュレーションのための組成物および方法 | |
| JP2021518125A5 (cg-RX-API-DMAC7.html) | ||
| JP2019504112A5 (cg-RX-API-DMAC7.html) | ||
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| JP2024515423A5 (cg-RX-API-DMAC7.html) | ||
| JP2024508896A5 (cg-RX-API-DMAC7.html) | ||
| WO2023278802A1 (en) | Formulations for oral delivery of nucleic acids | |
| JP2024516356A5 (cg-RX-API-DMAC7.html) | ||
| US20240043847A1 (en) | New therapy | |
| JP2019500334A (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター4(mct4)アンチセンスオリゴヌクレオチド(aso)阻害剤 | |
| JP2023529903A5 (cg-RX-API-DMAC7.html) | ||
| JP2024522996A5 (cg-RX-API-DMAC7.html) | ||
| JP2022543136A5 (cg-RX-API-DMAC7.html) | ||
| RU2766356C2 (ru) | Кобитолимод для применения при лечении воспалительного заболевания кишечника | |
| JP2025511854A (ja) | 非アルコール性脂肪肝疾患の治療 | |
| Wang et al. | Aptamer-functionalized-nanoflower loading allicin ameliorates obesity through regulating adipose tissue energy expenditure | |
| TW202434264A (zh) | 降低一級預防受試者中重大不良心血管事件風險之方法 | |
| CN111630169A (zh) | 用于治疗溃疡性结肠炎患者的组合物及其作为药物的用途 | |
| JP2024530030A (ja) | 非天然核酸リガンドを有効成分として含む三重陰性乳癌の治療のための薬学的組成物 | |
| CN113226461A (zh) | 新疗法 | |
| Gizem et al. | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 | |
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 |